Abstract
We tested the tachykinin NK(1) receptor antagonist WIN51708 (17betahydroxy17alphaethynyl5alphaandrostanol[3,2b]pyrimido[1,2-a]benzimidazole) in a behavioral sensitization model. Rats were given 7 days of cocaine then 7 days of withdrawal to induce sensitization. Thereafter, another 7 days of cocaine with WIN51708 (2 mg/kg i.p.) given 3.5 h after each cocaine injection was given. WIN51708 reversed sensitization but had no effect on controls. NK(1) receptor antagonists may have use in stimulant abuse and schizophrenia treatment.
Publication types
-
Comparative Study
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Androstanes / pharmacology*
-
Animals
-
Behavior, Addictive / chemically induced
-
Behavior, Addictive / physiopathology
-
Behavior, Addictive / prevention & control*
-
Behavior, Animal / drug effects
-
Benzimidazoles / pharmacology*
-
Cocaine / administration & dosage*
-
Cocaine / toxicity
-
Cocaine-Related Disorders / etiology
-
Cocaine-Related Disorders / prevention & control
-
Male
-
Neurokinin-1 Receptor Antagonists*
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Neurokinin-1 / physiology
-
Time Factors
Substances
-
Androstanes
-
Benzimidazoles
-
Neurokinin-1 Receptor Antagonists
-
Receptors, Neurokinin-1
-
WIN 51708
-
Cocaine